All In Biotech

Drug Trial Radar · NCT03960970

Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

Azithromycin-based Extended-spectrum Prophylaxis in Scheduled Cesarean Deliveries

Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Sep 15, 2019

Primary completion

Sep 30, 2019

Study completion Nov 30, 2020

Sponsor

Lead sponsor
RWJ Barnabas Health at Jersey City Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cesarean deliveries are the most common surgical procedure performed in the United States. A significant decrease in cesarean delivery associated maternal morbidity has been achieved with preoperative prophylactic single-dose cephalosporin, widely used before skin incision. Also, on laboring patients and/or with rupture of membranes, several studies suggest that adding azithromycin to standard cephalosporin prophylaxis is cost-effective and reduces overall rates of endometritis, wound infection, readmission, use of antibiotics and serious maternal events. Azithromycin has effective coverage against Ureaplasma, associated with increased rates of endometritis. Although two-drug regimen has been suggested for laboring and/or patients that undergo cesarean delivery, no studies have investigated the potential benefits of two-drug regimen in non-laboring patients.

Conditions

  • Endometritis
  • Cesarean Section; Infection
  • Wound Infection

Interventions

  • Azithromycin 500 mgDrug

    Additional IV Azithromycin 500 mg to Standard Prophylaxis

  • Mefoxin 2gDrug

    Standard Prophylaxis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rates of EndometritisTime frame: Up to 6 weeks after delivery
  2. Rates of Wound InfectionTime frame: Up to 6 weeks after delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jersey City Medical Center

    Jersey City, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.